| CY9D Stock | | | EUR 0.92 0.01 1.08% |
CFO
David Naim is Chief Financial Officer of Microbot Medical since 2016.
| Age | 50 |
| Tenure | 8 years |
| Phone | 781 875 3605 |
| Web | https://www.microbotmedical.com |
Microbot Medical Management Efficiency
The company has return on total asset
(ROA) of
(0.6524) % which means that it has lost $0.6524 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(1.1989) %, meaning that it generated substantial loss on money invested by shareholders. Microbot Medical's management efficiency ratios could be used to measure how well Microbot Medical manages its routine affairs as well as how well it operates its assets and liabilities.
Microbot Medical has accumulated 708
K in total debt with debt to equity ratio
(D/E) of 0.04, which may suggest the company is not taking enough advantage from borrowing. Microbot Medical has a current ratio of 17.06, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Microbot Medical until it has trouble settling it off, either with new capital or with free cash flow. So, Microbot Medical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Microbot Medical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Microbot to invest in growth at high rates of return. When we think about Microbot Medical's use of debt, we should always consider it together with cash and equity.
Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts. MICROBOT MEDICAL operates under Medical Instruments Supplies classification in Germany and is traded on Frankfurt Stock Exchange. It employs 14 people. Microbot Medical (CY9D) is traded on Frankfurt Exchange in Germany and employs 20 people.
Management Performance
Microbot Medical Leadership Team
Elected by the shareholders, the Microbot Medical's board of directors comprises two types of representatives: Microbot Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Microbot. The board's role is to monitor Microbot Medical's management team and ensure that shareholders' interests are well served. Microbot Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Microbot Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Prattipati Laxminarain, Independent Director | |
| Yoav Waizer, Independent Director | |
| Simon Sharon, Chief Technology Officer | |
| Rachel Vaknin, Chief Officer | |
| Harel Gadot, Chairman of the Board, President, Chief Executive Officer | |
| Tal Wenderow, Independent Director | |
| Yoseph Bornstein, Independent Director | |
| Eyal MD, Chief Board | |
| Aileen Stockburger, Independent Director | |
| MSc MBA, CTO GM | |
| Pr DSc, Scientific CoFounder | |
| David Naim, Chief Financial Officer | |
| Eyal Morag, Chief Medical Officer | |
| Scott Burell, Independent Director | |
| Martin Madden, Independent Director | |
Microbot Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Microbot Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Microbot Stock
When determining whether Microbot Medical is a good investment, qualitative aspects like company
management, corporate governance, and ethical practices play a significant role. A
comparison with peer companies also provides context and helps to understand if Microbot Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Microbot Medical Stock.
Highlighted below are key reports to facilitate an investment decision about Microbot Medical Stock: Check out
Trending Equities to better understand how to build diversified portfolios, which includes a position in Microbot Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in unemployment.
For more detail on how to invest in Microbot Stock please use our
How to Invest in Microbot Medical guide.
You can also try the
Money Managers module to screen money managers from public funds and ETFs managed around the world.
Please note, there is a significant difference between Microbot Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Microbot Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Microbot Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.